- Home
- PMCB vs BIAF Comparison
PMCB vs BIAF Comparison
Compare PMCB & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMCB
- BIAF
- Stock Information
- Founded
- PMCB 1996
- BIAF 2014
- Country
- PMCB United States
- BIAF United States
- Employees
- PMCB N/A
- BIAF N/A
- Industry
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- PMCB Health Care
- BIAF Health Care
- Exchange
- PMCB Nasdaq
- BIAF Nasdaq
- Market Cap
- PMCB 6.6M
- BIAF 7.6M
- IPO Year
- PMCB N/A
- BIAF 2022
- Fundamental
- Price
- PMCB $0.93
- BIAF $0.18
- Analyst Decision
- PMCB
- BIAF Hold
- Analyst Count
- PMCB 0
- BIAF 1
- Target Price
- PMCB N/A
- BIAF N/A
- AVG Volume (30 Days)
- PMCB 106.5K
- BIAF 12.0M
- Earning Date
- PMCB 09-15-2025
- BIAF 11-13-2025
- Dividend Yield
- PMCB N/A
- BIAF N/A
- EPS Growth
- PMCB N/A
- BIAF N/A
- EPS
- PMCB 0.01
- BIAF N/A
- Revenue
- PMCB N/A
- BIAF $7,681,059.00
- Revenue This Year
- PMCB N/A
- BIAF N/A
- Revenue Next Year
- PMCB N/A
- BIAF $20.04
- P/E Ratio
- PMCB $160.47
- BIAF N/A
- Revenue Growth
- PMCB N/A
- BIAF 4.99
- 52 Week Low
- PMCB $0.80
- BIAF $0.16
- 52 Week High
- PMCB $2.42
- BIAF $2.26
- Technical
- Relative Strength Index (RSI)
- PMCB 44.27
- BIAF 36.96
- Support Level
- PMCB $1.00
- BIAF $0.24
- Resistance Level
- PMCB $1.08
- BIAF $0.45
- Average True Range (ATR)
- PMCB 0.08
- BIAF 0.03
- MACD
- PMCB -0.00
- BIAF 0.00
- Stochastic Oscillator
- PMCB 2.95
- BIAF 3.60
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.